Cingulate (CINGW) Net Shares Issued and Repurchased (2021 - 2026)
Cingulate's (CINGW) quarterly Net Shares Issued and Repurchased came in at $3860.0 in Q2 2026, down 93.67% on a YoY basis from $61005.0 in Q2 2025, and down 99.56% quarter-over-quarter from $868901.0 in Q4 2025.
Analysis
Cingulate (CINGW) Net Shares Issued and Repurchased (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Net Shares Issued and Repurchased for 6 consecutive years, with $3860.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Shares Issued and Repurchased fell 93.67% year-over-year to $3860.0; the trailing twelve-month figure through Jun 2026 stood at $3860.0 (down 93.67% YoY), and the FY2025 full-year result was $868901.0, up 875.94% from the prior year.
- Net Shares Issued and Repurchased retreated to $3860.0 in Q2 2026 per CINGW's latest filing, from $868901.0 in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $868901.0 in Q4 2025 and bottomed at $2000.0 in Q3 2024.
- Historically, Net Shares Issued and Repurchased has averaged $151355.9 across 5 years, with a median of $61005.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Net Shares Issued and Repurchased tumbled 98.08% in 2024, then jumped 27541.9% in 2025.
- Over 5 years, Net Shares Issued and Repurchased stood at $18017.0 in 2022, then sank by 85.29% to $2651.0 in 2023, then soared by 3258.43% to $89032.0 in 2024, then jumped by 875.94% to $868901.0 in 2025, then plunged by 99.56% to $3860.0 in 2026.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $3860.0, $868901.0, and $552838.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn | - |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn | - |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | -3.07 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | - |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 3,860.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,860.00 |
| Dec 31, 2025 | 868,901.00 |
| Sep 30, 2025 | 552,838.00 |
| Jun 30, 2025 | 61,005.00 |
| Mar 31, 2025 | 248,428.00 |
| Dec 31, 2024 | 89,032.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 69,038.00 |
| Mar 31, 2024 | 15,994.00 |
| Dec 31, 2023 | 2,651.00 |
| Sep 30, 2023 | 104,066.00 |
| Jun 30, 2023 | 127,758.00 |
| Mar 31, 2023 | 19,225.00 |
| Dec 31, 2022 | 18,017.00 |
| Sep 30, 2022 | 29,721.00 |
| Jun 30, 2022 | 17,517.00 |
| Mar 31, 2022 | 342,999.00 |
| Dec 31, 2021 | 523,285.00 |